The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
The company posted net profit of Rs.81.33 crores for the quarter ended September 30, 2021.
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
The plant is expected to start commercial operations from Q4FY24
Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021
Since its inception, the company has either acquired or taken a majority stake in five companies
The drug is being developed at lab scale for the first-line of treatment of Covid-19
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients
Subscribe To Our Newsletter & Stay Updated
